Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of …

NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be exhibiting and showcasing new data at the Heart Failure Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020 taking place from September 30th – October 6th, 2020.

The Company will host a booth and will be available online throughout the entire conference to discuss how Daxor’s BVA-100® blood test improves heart failure outcomes and answer questions. New data titled “ Red Cell Volume Phenotypes in Hospitalized Heart Failure Patients” (Poster #132) and “Cost-effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure Patients” ( Poster #331) will be highlighted in the Poster Hall accompanied by a narrative from the principal investigators.

“The HFSA Annual Scientific Meeting is an exciting venue to increase awareness and utilization

Read More